Market open
UroGen Pharma/$URGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Ticker
$URGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
234
ISIN
IL0011407140
Website
UroGen Pharma Metrics
BasicAdvanced
$455M
-
-$3.04
0.67
-
Price and volume
Market cap
$455M
Beta
0.67
52-week high
$20.70
52-week low
$8.94
Average daily volume
662K
Financial strength
Current ratio
5.647
Quick ratio
5.132
Long term debt to equity
-268.95
Total debt to equity
-271.994
Interest coverage (TTM)
-7.56%
Management effectiveness
Return on assets (TTM)
-29.80%
Return on equity (TTM)
319.73%
Valuation
Price to revenue (TTM)
4.885
Price to book
-9.79
Price to tangible book (TTM)
-9.79
Price to free cash flow (TTM)
-4.179
Growth
Revenue change (TTM)
8.98%
Earnings per share change (TTM)
-5.79%
3-year revenue growth (CAGR)
19.29%
3-year earnings per share growth (CAGR)
-15.50%
What the Analysts think about UroGen Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
UroGen Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
UroGen Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
UroGen Pharma News
AllArticlesVideos
UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript
Seeking Alpha·3 days ago
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Business Wire·2 weeks ago
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $455M as of May 15, 2025.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of May 15, 2025.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.